Polycyclic aromatic hydrocarbons and perinatal outcomes: a scoping review

Srirupa Hari Gopal1, Melissa A Suter2, Bhagavatula Moorthy3

  • 1Dept. of Pediatrics, Division of Neonatology, SSM Health Cardinal Glennon Children's Hospital/Saint Louis University, St Louis, MO, USA. srirupa.harigopal@ssmhealth.com.

Pediatric Research
|July 3, 2026
PubMed
Summary

Polycyclic aromatic hydrocarbons (PAHs) are hazardous pollutants linked to infertility, preterm birth, and adverse fetal development. Prenatal and childhood exposure to PAHs also increases risks for various childhood disorders, including asthma and autism spectrum disorders.

Related Concept Videos

Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
Development of the Oral Microbiota01:28

Development of the Oral Microbiota

The establishment of the oral microbiome begins before birth, challenging the long-held belief that the fetal oral cavity is sterile. The presence of oral microbes such as Streptococcus and Fusobacterium in amniotic fluid suggests that microbial exposure may occur in utero, potentially through translocation from the maternal oral or gastrointestinal tract. This early colonization primes the neonatal immune system and sets the stage for subsequent microbial succession. Maternal health,...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...